-
Todd Schermerhorn has been named senior vice president and chief financial officer of C.R. Bard (Murray Hill, New Jersey), replacing Charles Slacik, who has resigned.
-
-
The explosion of Internet-based advertising for genetic tests has provoked a sharp reaction from the European Unions top advisers on ethics. They issued a call for caution last month and promised to investigate the matter closely.
-
CardioTech International (Woburn, Massachusetts) said it would complete the acquisition of Gish Biomedical (Rancho Santa Margarita, California) by April 7. The value of the stock-for-stock deal has not been disclosed.
-
Abiomed (Danvers, Massachusetts) last month rolled out plans to develop a new line of ventricular-assist devices, suggesting both a return to its initial development effort and an inflection point in its progress with the AbioCor replacement heart program.
-
AST Products (Billerica, Massachusetts), a developer of water-based coatings for medical devices, has completed a licensing agreement with MicroPort Medical (Shanghai, China) for its LubriLAST coating.
-
Women who undergo open-heart surgery are more likely than men to develop acute renal failure (ARF), according to research conducted at The Cleveland Clinic (Cleveland, Ohio).
-
Senior management at CryoCath Technologies (Montreal, Quebec) was elated over the result of an FDA advisory panel meeting last month, despite a list of conditions the company must now address.
-
In one of the more bizarre stories of the year, the FDA has uncovered files of counterfeit Procrit (epoetin alfaJohnson & Johnson) in routine surveillance.
-
The true function of the meniscofemoral ligaments remains unclear, but it may have profound implications for treatment of PCL-deficient knees and lateral meniscal tears.
